Inspire Announces Oral Presentation of Phase 2 Epinastine Nasal Spray Data at American College of Allergy, Asthma & Immunology Meeting
The abstract will be available following the conference on Inspire's website, www.inspirepharm.com.
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Inspire Pharmaceuticals, Inc.
Jenny Kobin, VP, Investor Relations and
Corporate Communications, 919-941-9777, Ext. 219
Dan Budwick, 212-477-9007, Ext. 14
Posted: November 2007